Research ArticleOpen AccessGoogle Scholar indexed
Recurrent Oxaliplatin-Induced Immune Hemolytic Anemia by Chemotherapy for Metastatic Colon Cancer: A Case Report
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 1 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 2 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 3 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 4 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 5 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 6 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
- 7 Department of Medical Oncology, Paoli-Calmettes Institute, Marseille, France.
Journal of Cancer Therapy·Volume 04 (2013)·Pages 159–160·Published 7 February 2013·DOI10.4236/jct.2013.41022
Copy link · social · email
Abstract
We report herein the case of a 55 - year - old man who presented an acute hemolysis following a 6th cycle of FOLFOX regimen for a metastatic colorectal cancer; this patient had previously received 12 cycles in an adjuvant setting. He had presented attenuated signs during the previous cycle. This corresponded to an oxaliplatin-induced immune hemolytic anemia. This unfrequent side effect of oxaliplatin needs to be known in order to avoid severe complications.
KeywordsOxaliplatineHemolysisAuto-ImmuneColorectal Cancer
- J. Desrame, H. Broustet, P. Darodes de Tailly, D. Girard and J. M. Saissy, “Oxaliplatin-Induced Haemolytic Anaemia,” Lancet, Vol. 354, No. 9185, 1999, pp. 1179-1180. doi:10.1016/S0140-6736(99)03827-1
- S. Buti, M. Riccò, M. D. Chiesa, B. Copercini, G. Tomasello, M. Brighenti and R. Passalacqua, “Oxaliplatin-Induced Hemolytic Anemia during Adjuvant Treatment of a Patient with Colon Cancer: A Case Report,” Anticancer Drugs, Vol. 18, No. 3, 2007, pp. 297-300. doi:10.1097/CAD.0b013e3280102f4b
- J. I. Lai, W. S. Wang “Acute Hemolysis after Receiving Oxaliplatin Treatment: A Case Report and Literature Review,” Pharmacy World & Science, Vol. 31, No. 5, 2009, pp. 538-541. doi:10.1007/s11096-009-9313-0
- I. Ito, Y. Ito, M. Mizuno, Y. Suzuki, K. Yasuda, T. Ozaki, et al., “A Rare Case of Acute Kidney Injury Associated with Autoimmune Hemolytic Anemia and Thrombocytopenia after Long-Term Usage of Oxaliplatin,” Clinical and Experimental Nephrology, Vol. 16, No. 3, 2012, pp. 490-494. doi:10.1007/s10157-012-0620-8
- A. Ulusakarya, S. Misra, M. Haydar, H. Habert, V. Castagne, Y. Gumus, et al., “Acute Renal Failure Related to Oxaliplatin-Induced Intravascular Hemolysis,” Medical Oncology, Vol. 27, No. 4, 2010, pp. 1425-1426. doi:10.1007/s12032-009-9263-3
- A. Salama, “Drug-Induced Immune Hemolytic Anemia,” Expert Opinion on Drug Safety, Vol. 8, No. 1, 2009, pp. 73-79. doi:10.1517/14740330802577351
- G. Garratty, “Drug-Induced Immune Hemolytic Anemia,” Hematology ASH Education Program, Vol. 2009, No. 1, 2009, pp. 73-79.